SCHEMBL3728323

SCHEMBL3728323

CC1CN(c2ccc(C(F)(F)F)cc2-c2cnc(N3CCC(S(C)(=O)=O)CC3)nc2)CCN1C(=O)Cn1c(=O)[nH]c2ccccc21

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CXCR3 P49682 6/20 0.48
KCNH2 Q12809 3/20 0.48
GRIN1 Q05586 8/20 0.40
GRIN2B Q13224 8/20 0.40
DGAT1 O75907 1/20 0.39
CHRM1 P11229 5/20 0.38
CHRM2 P08172 4/20 0.38
CHRM3 P20309 3/20 0.38
ABCB11 O95342 1/20 0.36
HTR1A P08908 1/20 0.36
ADRA2A P08913 1/20 0.36
ADORA3 P0DMS8 1/20 0.36
DRD1 P21728 1/20 0.36
TBXA2R P21731 1/20 0.36
SLC6A4 P31645 1/20 0.36
ADRA1A P35348 1/20 0.36
OPRM1 P35372 1/20 0.36
DRD3 P35462 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL115409 0.92 CXCR3 (0.57) CXCR3KCNH2GRIN1GRIN2BCHRM1
SCHEMBL113350 0.92 CXCR3 (0.51) CXCR3KCNH2GRIN1GRIN2BCHRM1
SCHEMBL165523 0.91 CXCR3 (0.44) CXCR3KCNH2GRIN1GRIN2BCHRM1
SCHEMBL169464 0.90 CXCR3 (0.52) CXCR3KCNH2CHRM1CHRM2
SCHEMBL15925565 0.85 CXCR3 (0.44) CXCR3KCNH2GRIN1GRIN2BCHRM1
SCHEMBL164266 0.84 CXCR3 (0.38) CXCR3KCNH2DGAT1CHRM1CHRM2
SCHEMBL113184 0.83 CXCR3 (0.40) CXCR3DGAT1CHRM1CHRM2CHRM3
SCHEMBL164210 0.82 CXCR3 (0.60) CXCR3KCNH2GRIN1GRIN2B
SCHEMBL167594 0.82 CXCR3 (0.46) CXCR3KCNH2GRIN1GRIN2B
SCHEMBL165135 0.82 CXCR3 (0.55) CXCR3KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100280028-A1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-11-04 US claimed
EP-2424840-B1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INT (DE) 2014-08-06 EP disclosed
US-8450317-B2 CXCR3 receptor antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-05-28 US disclosed
US-8450317-B2 CXCR3 receptor antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-05-28 US disclosed
US-8450317-B2 CXCR3 receptor antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-05-28 US disclosed
WO-2010126811-A1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-11-04 WO disclosed
US-20100280028-A1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-11-04 US disclosed
US-20100280028-A1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-11-04 US disclosed
US-20100280028-A1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-11-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100280028-A1 CXCR3 RECEPTOR ANTAGONISTS CXCR3, CXCR1, CXCR2 CXCR3 1/4885KCNH2 1561/4885GRIN1 677/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.